Philip Russmeyer: Revolutionising clinical trials with true data anonymization
Send us Fan Mail
This week we speak to Philip Russmeyer, Founder & CEO of Fitfile, about the promises that true data anonymization holds for transforming clinical trials.
We dive into the differences between tokenization, anonymization and pseudonymisation of data. And how the difference is whether individuals can ever be identified or if the data is masked with a token that can potentially be removed.
The risk of secondary use of data that has been tokenized has held back research and data sharing between healthcare and life sciences. One of the reasons is that collecting consent from…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.